A prospective cohort study on the analysis of REV7 in pancreatic cancer using EUS-TA specimens and investigating the association between REV7 expression intensity and prognosis

A prospective cohort study on the analysis of REV7 in pancreatic cancer using EUS-TA specimens and investigating the association between REV7 expression intensity and prognosis - REV7 in pancreatic cancer analysis and prognosis study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057135

Enrollment

100

Registered

2025-03-01

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 18 years of age or older 2. Cases diagnosed as unresectable pancreatic cancer by EUS-TA 3. Cases with a pathological diagnosis of adenocarcinoma or adenosquamous carcinoma

Exclusion criteria

Exclusion criteria: 1. Cases that refused to be the subject of this study

Design outcomes

Primary

Measure	Time frame
the expression intensity of REV7	—

Countries

Japan

Contacts

Public ContactKosuke Okuwaki

Kitasato University School of Medicine Department of Gastroenterology

kokuwaki@kitasato-u.ac.jp+81-42-778-8111

Outcome results